Can molotinib be purchased in China?

Molotinib is not currently available in China because the drug has not yet been approved for marketing in China. Although molotinib was first approved for marketing in the United States in September 2023, it has not yet received approval and marketing authorization from the Food and Drug Administration in China. This means that patients in China cannot purchase this drug through formal channels such as hospitals and pharmacies. Molotinib is an innovative drug primarily used to treat a specific type of myelofibrosis, a disease that affects hematopoietic function due to the proliferation of collagen fibers in bone marrow hematopoietic tissue. Specifically, it is indicated for the treatment of moderate or high-risk myelofibrosis (MF) in adults with anemia, including primary MF or secondary MF (post-polycythemia vera and post-idiopathic thrombocythemia). The development of molotinib provides new treatment options for these patients and is expected to improve their condition and quality of life. However, since the drug is not yet available in China, patients and medical professionals need to continue to pay attention to its development and approval progress. For patients who are in urgent need of this drug, they can consult some overseas medical institutions for help.